Randomized Trial on 14-Days Versus 7-Days of Esomeprazole, Moxifloxacin and Amoxicillin for Second-Line or Rescue Treatment of Helicobacter pylori Infection

Miehlke, Stephan; Krasz, Susanne; Schneider-Brachert, Wulf; Kuhlisch, Eberhard; Berning, Marco; Madisch, Ahmed; Laaß, Martin W.; Neumeyer, Michael; Jebens, Claus; Zekorn, C; Knoth, Holger; Stolte, Manfred; Lehn, Norbert

doi:10.1016/s0016-5085(11)60237-0

Cited by 20 publications

(27 citation statements)

References 24 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, increasing the duration of therapy was expected to increase the eradication rate, but the expected increased did not materialize, most likely because of coincident marked increase in the prevalence of resistance to moxifloxacin [32]. Finally, in a recent randomized study, 14 days of treatment significantly increased the eradication compared with 7-day regimen [51].…”

Section: Discussionmentioning

confidence: 95%

Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments

Gisbert¹,

Romano²,

Molina–Infante³

et al. 2015

Digestive and Liver Disease

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments

Gisbert¹,

Romano²,

Molina–Infante³

et al. 2015

Digestive and Liver Disease

View full text Add to dashboard Cite

“…In addition, recent studies have demonstrated that longer duration with 14-day fluoroquinolone triple therapy provided treatment success of 95% (Miehlke et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand

Prapitpaiboon¹,

Mahachai²,

Vilaichone³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Levofloxacin is an effective medication for second line Helicobacter pylori (H. pylori) eradication. However, limited studies have approved its use as an effective antibiotic in first line therapy. Dexlansoprazole is a new PPI and lacks of evidence in support of a role in H. pylori eradication. This study was designed to evaluate efficacy of levofloxacin-dexlansoprazole-based quadruple therapy for H. pylori eradication in Thailand. Materials and Methods: This prospective randomized control study was performed during June 2014 to December 2014. H. pylori infected gastritis patients were randomized to receive 7-or 14-day levofloxacin-dexlansoprazole based on quadruple therapy (levofloxacin 500 mg OD, dexlansoprazole 60 mg bid, clarithromycin MR 1000 mg OD, bismuth subsalicylate 1048 mg bid). CYP2C19 genotyping and antibiotic susceptibility tests were conducted for all patients. A 13C urea breath test was performed to confirm H. pylori eradication at least 4 weeks after treatment. Results: A total of 100 patients were enrolled, comprising 44 males and 56 females (mean age of 52.6 years). Eradication rate by PP analysis was 85.7% (42/49) with the 7-day regimen and 98% (48/49) with the 14-day regimen (85.7% vs 98%; p-value=0.059). ITT analysis was 84% and 96% with 7-and 14-day regimens, respectively (84% vs 96%; p-value=0.092). Antibiotic susceptibility testing demonstrated 35.1% resistance to metronidazole, 18.3% to clarithromycin, and 13.5% to levofloxacin. CYP2C19 genotyping revealed 54.1% RM, 34.7% IM and 11.2% PM. The 14-day regimen provided 100% eradication in patients with clarithromycin or dual clarithromycin and metronidazole H. pylori resistant strains. Moreover, the eradication rate was 96.6% in patients with CYP2C19 genotype RM. Conclusions: The 14-day levofloxacin-dexlansoprazole based quadruple therapy provides high H. pylori eradication regardless of CYP2C19 genotype, clarithromycin or dual clarithromycin and metronidazole resistant strains. This regimen could be use as an alternative first line therapy for H. pylori eradication in Thailand.

show abstract

“…There are no comparative data on whether the dose increase enhanced the efficacy of therapy. It has also been indicated in many other studies that moxifloxacin‐based triple therapy is effective and well tolerated …”

Section: Discussionmentioning

confidence: 99%

Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

Rakici

Akdoğan

Bedir

et al. 2014

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

Randomized Trial on 14-Days Versus 7-Days of Esomeprazole, Moxifloxacin and Amoxicillin for Second-Line or Rescue Treatment of Helicobacter pylori Infection

Cited by 20 publications

References 24 publications

Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments

Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments

High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand

Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

Contact Info

Product

Resources

About